Last edition
News about "NXC-201 "
Immix Biopharma Prices USD 100 Million Stock and Pre-Funded Warrant Offering
Immix Biopharma has priced its USD 100 million offering of common stock and pre-funded warrants, with plans to use the proceeds—alongside existing cash reserves—to advance the development of NXC-201 and support working capital and general corporate needs.
NXC-201 | 08/12/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members